Form 4: Abbott Laboratories Director Robert J. Alpern Reports Stock Equivalent Unit Acquisition

Director Robert J. Alpern reports acquisition of 69 stock equivalent units in Abbott Laboratories through director fees credited to a grantor trust.

Summary

• Robert J. Alpern, a director of Abbott Laboratories, reported a transaction on March 31, 2024.
• Alpern acquired 69 stock equivalent units as director fees credited to a grantor trust.
• These units earn the same return as if the fees were invested in Abbott shares.
• The price per unit was $113.66.
• Following the transaction, Alpern beneficially owns 9,628 stock equivalent units.
• These units are payable in cash generally at age 65 or upon retirement from the board.
• The balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a director increasing their stake in the company, which is generally viewed favorably, but it's a routine transaction.

Positives

• The acquisition of stock equivalent units demonstrates the director's continued investment in Abbott Laboratories.
• The dividend reinvestment feature further increases the director's stake.

Industry Context

This filing is a routine disclosure of a director's acquisition of stock equivalent units, a common form of compensation for board members. It reflects ongoing alignment of interests between management and shareholders.

Comparison to Industry Standards

• Director compensation in the form of stock or stock equivalent units is a common practice among large publicly traded companies like Abbott Laboratories.
• Companies such as Johnson & Johnson and Pfizer also utilize similar compensation structures to align director interests with shareholder value.
• The specific number of units acquired and the terms of the grantor trust are specific to Abbott Laboratories' compensation policies.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It reinforces the alignment of interests between the director and shareholders.

Key Dates